Asset Details
Do you wish to reserve the book?
Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation
Do you wish to request the book?
Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation
2024
Overview
The present study investigated the relationship between
MSH3
and
MSH6
genes in lung cancer patients. Genotyping of lung cancer patients and healthy controls was performed. Odds ratio values were calculated and survival analysis performed. Patients with mutant genotype (TT) for
MSH6
polymorphism have 1.5-fold risk for the development of lung cancer (
p
= 0.03). For non-smokers, the mutant-type genotype had a threefold increased risk of lung cancer (
p
= 0.01). Patients administered with docetaxel and carbo/cisplatin and carrying GT genotype for
MSH6
polymorphism, patients reported a decrease in median survival time (4.9 vs 9.13 months).
MSH3
and
MSH6
polymorphisms are involved in modulating the risk towards lung cancer.
MSH6
polymorphism is associated with high mortality rate for patients undergoing cisplatin and docetaxel chemotherapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/337
/ 631/67
/ 631/80
/ Adult
/ Aged
/ Carboplatin - therapeutic use
/ DNA-Binding Proteins - genetics
/ Female
/ Genes
/ Genetic Predisposition to Disease
/ Genotype
/ Humanities and Social Sciences
/ Humans
/ Lung Neoplasms - drug therapy
/ Male
/ MSH3
/ MSH6
/ Mutants
/ MutS Homolog 3 Protein - genetics
/ Patients
/ Pharmacy
/ Polymorphism, Single Nucleotide
/ Proteins
/ Science
/ Survival
/ Tumors
